Course: Pathways to Personalization: Implementing Biologics in COPD Treatment
CME Credits: 0.75
Released: 2025-11-12
COPD is a highly heterogeneous condition that affects patients across a broad range of severities. Historically, clinicians have had limited treatment options for patients who remain symptomatic despite maximal inhaled or standard therapy. With growing insight into COPD’s molecular mechanisms, biologic therapies have emerged as a new frontier, leading to FDA approval of dupilumab in 2024 and mepolizumab in 2025, with additional agents in development. This program aims to test clinician knowledge regarding the evolution of biologic treatments and their role in shifting COPD care from a uniform to a precision-based approach. Clinicians will receive immediate feedback on their clinical decision-making in each case, with expert faculty providing guidance on optimal care.
Upon completion of this educational activity, participants should be able to:
View Full Course